NLRP3 and breast carcinoma: Moreover, MEG3 was found to promote cisplatin-induced pyroptosis by promoting the NLRP3/caspase-1/GSDMD axis, implying that MEG3 may be an effective therapeutic target for enhancing breast cancer chemotherapy (34).